Summary
BeiGene, Ltd. (ONC) reported a strong third quarter of 2023, with total revenues soaring to $781.3 million, a significant increase of 101.6% year-over-year. This growth was primarily driven by a substantial 70.3% increase in product revenue, reaching $595.3 million, largely attributed to the continued strong performance of BRUKINSA, which saw a 130.0% rise in global sales. The company also benefited from increased collaboration revenue, notably from the termination of agreements with Novartis, which recognized remaining deferred revenue. Despite a reported net loss of $514.2 million for the first nine months of the year, the quarter itself showed a net income of $215.4 million, indicating a positive operational trend. The company ended the quarter with a robust cash position of $3.1 billion, positioning it well to fund its operations for at least the next 12 months. Key strategic developments include regaining global rights to TEVIMBRA, which strengthens the company's oncology portfolio, and receiving positive opinions for BRUKINSA's reimbursement in the UK and for a new indication in the EU. Management highlighted plans to improve operating leverage and moderate expense growth. The company's continued investment in R&D and commercial capabilities, including the ongoing construction of its Hopewell facility in New Jersey, underscores its commitment to expanding its global reach and product pipeline.
Financial Highlights
52 data points| Revenue | $781.31M |
| Cost of Revenue | $96.31M |
| Gross Profit | $685.00M |
| R&D Expenses | $453.26M |
| SG&A Expenses | $365.71M |
| Operating Expenses | $818.97M |
| Operating Income | -$133.97M |
| Interest Expense | $6.63M |
| Net Income | $215.41M |
| EPS (Basic) | $0.16 |
| EPS (Diluted) | $0.15 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.39B |
Key Highlights
- 1Total revenues surged by 101.6% year-over-year to $781.3 million in Q3 2023.
- 2Product revenue increased by 70.3% to $595.3 million, driven by strong global sales of BRUKINSA (+130.0%).
- 3Collaboration revenue grew significantly due to deferred revenue recognition from Novartis terminations, reaching $186.0 million.
- 4Regained global rights to TEVIMBRA (tislelizumab), enhancing the company's oncology portfolio.
- 5Received positive opinions for BRUKINSA reimbursement in the UK (NHS) and for a new indication in the EU (follicular lymphoma).
- 6Reported a net income of $215.4 million for Q3 2023, a significant turnaround from the net loss in the prior-year period.
- 7Ended the quarter with $3.1 billion in cash, cash equivalents, and restricted cash, providing ample liquidity.